pteridines has been researched along with maytansine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akbulut, Ö; Akyol, A; Alkan, C; Borgoni, S; Durmuş, S; Eyüpoğlu, E; Kütük, Ö; Raza, U; Saatci, Ö; Şahin, Ö; Wiemann, S | 1 |
| Classe, JM; Ferron, G; Floquet, A; Freyer, G; Hardy-Bessard, AC; Kurtz, JE; Lécuru, F; Motte-Rouge, T; Pautier, P | 1 |
1 review(s) available for pteridines and maytansine
| Article | Year |
|---|---|
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Azepines; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Genes, BRCA1; Genes, BRCA2; Humans; Immunoconjugates; Immunotherapy; Isoxazoles; Maintenance Chemotherapy; Maytansine; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Pteridines; Pyrazines; Pyrimidines | 2021 |
1 other study(ies) available for pteridines and maytansine
| Article | Year |
|---|---|
Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; bcl-X Protein; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Maytansine; Mice; Phosphorylation; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pteridines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Xenograft Model Antitumor Assays | 2018 |